Pfizer Sues Alembic Over Lyrica ANDA

Law360, New York (December 8, 2011, 6:30 PM EST) -- Pfizer Inc. and Northwestern University launched a suit in Delaware federal court Thursday accusing Alembic Ltd. of infringing a patent for nerve pain drug Lyrica by seeking approval to sell a generic version of the drug.

Gujarat, India-based Alembic submitted an abbreviated new drug application to the U.S. Food and Drug Administration that allegedly infringes the claims of U.S. Patent Number 6,197,819, titled “Gamma amino butyric acid analogs and optical isomers,” according to the complaint.

The patent covers pregabalin, sold by Pfizer under the name Lyrica,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.